{"id":"naltrexone-intramuscular-suspension","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1201149","moleculeType":"Small molecule","molecularWeight":"377.87"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to opioid receptors, naltrexone prevents opioids from exerting their effects, which can help to reduce cravings and prevent relapse in individuals with opioid use disorder. This mechanism of action is thought to be responsible for the therapeutic effects of naltrexone in treating addiction.","oneSentence":"Naltrexone is an opioid receptor antagonist that blocks the action of opioids at their receptor sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:33.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of opioid dependence"},{"name":"Alcohol dependence"}]},"trialDetails":[{"nctId":"NCT05028062","phase":"PHASE4","title":"Naltrexone in AUD Reward Drinkers","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-03-07","conditions":"Alcohol Use Disorder, Alcoholism","enrollment":60},{"nctId":"NCT02324725","phase":"PHASE4","title":"Biomarkers of Injectable Extended Release Naltrexone Treatment","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-10","conditions":"Heroin Dependence, Opioid Dependence","enrollment":32},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT02478489","phase":"PHASE4","title":"Alcohol Disorder hOsPital Treatment Trial","status":"COMPLETED","sponsor":"Boston University","startDate":"2016-06","conditions":"Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder","enrollment":248},{"nctId":"NCT02978417","phase":"PHASE4","title":"Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-09-21","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT00834080","phase":"PHASE3","title":"ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2009-03","conditions":"Opiate Dependence","enrollment":38},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT00156923","phase":"PHASE3","title":"ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2003-10","conditions":"Alcoholism","enrollment":108},{"nctId":"NCT01218958","phase":"PHASE3","title":"ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2002-02","conditions":"Alcoholism","enrollment":624},{"nctId":"NCT00511836","phase":"PHASE4","title":"ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2007-07","conditions":"Alcohol Dependence","enrollment":31},{"nctId":"NCT00678418","phase":"PHASE3","title":"ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2008-06","conditions":"Opiate Dependence","enrollment":250},{"nctId":"NCT01218984","phase":"PHASE2","title":"ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2002-03","conditions":"Opiate Dependence","enrollment":27},{"nctId":"NCT01563718","phase":"PHASE4","title":"Pre-Release VIVITROL for Opioid Dependent Inmates","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2012-03","conditions":"Substance-Related Disorders","enrollment":26},{"nctId":"NCT00501631","phase":"PHASE3","title":"ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2007-07","conditions":"Alcohol Dependence","enrollment":300},{"nctId":"NCT01218997","phase":"PHASE3","title":"ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2003-08","conditions":"Alcoholism","enrollment":436},{"nctId":"NCT01218971","phase":"PHASE3","title":"ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2002-08","conditions":"Alcohol Dependence","enrollment":332},{"nctId":"NCT00156936","phase":"PHASE3","title":"ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])","status":"TERMINATED","sponsor":"Alkermes, Inc.","startDate":"2004-08","conditions":"Alcoholism, Opiate Dependence","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Long-acting naltrexone","Extended-release naltrexone","XR-NTX","Vivitrol"],"phase":"phase_3","status":"active","brandName":"Naltrexone intramuscular suspension","genericName":"Naltrexone intramuscular suspension","companyName":"University of Oslo","companyId":"university-of-oslo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naltrexone is an opioid receptor antagonist that blocks the action of opioids at their receptor sites. Used for Treatment of opioid dependence, Alcohol dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}